MCL1 and cancer: We demonstrate that dual inhibition of BCL2/XL and MCL1 is synergistic in 4 out of 5 tested HGSOC models, and that treatment efficacy is significantly enhanced by LbL NP‐mediated delivery to cancer cells in vitro.